Clinical and pathological insights into the dynamic nature of the white matter multiple sclerosis plaque

Annals of Neurology

Volumn 78, Issue 5, 2015, Pages 710-721

  Frischer, Josa M ^a   Weigand, Stephen D ^b   Guo, Yong ^c   Kale, Nilufer ^c   Parisi, Joseph E ^c   Pirko, Istvan ^c   Mandrekar, Jay ^b   Bramow, Stephan ^d,e   Metz, Imke ^f   Brück, Wolfgang ^f   Lassmann, Hans ^g   Lucchinetti, Claudia F ^c  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Mayo Clinic College of Medicine   (United States)

^c MAYO CLINIC   (United States)

^d Copenhagen University Hospital ^*  (Denmark)

^e International Center for Research and Research Training in Endocrine Disruption of Male Reproduction and Child Health   (Denmark)

^f UNIVERSITY OF GÖTTINGEN   (Germany)

^g Medical University of Vienna   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGE; AGED; ARTICLE; AUTOPSY; BRAIN TISSUE; DEMYELINATION; DISEASE COURSE; DISEASE DURATION; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MICROGLIA; MULTIPLE SCLEROSIS; NEUROPATHOLOGY; PRIORITY JOURNAL; WHITE MATTER; AGING; DEMYELINATING DISEASE; MIDDLE AGED; PATHOLOGY; SEXUAL DEVELOPMENT; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGING; AUTOPSY; DEMYELINATING DISEASES; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MICROGLIA; MIDDLE AGED; MULTIPLE SCLEROSIS; MULTIPLE SCLEROSIS, CHRONIC PROGRESSIVE; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; SEX CHARACTERISTICS; WHITE MATTER; YOUNG ADULT;

EID: 84945133122     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.24497     Document Type: Article

References (41)

1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG,. Multiple sclerosis. N Engl J Med 2000; 343: 938-952.
2. Lassmann H, Bruck W, Lucchinetti CF,. The immunopathology of multiple sclerosis: an overview. Brain Pathol 2007; 17: 210-218.
3. Lassmann H, van Horssen J, Mahad D,. Progressive multiple sclerosis: pathology and pathogenesis. Nat Rev Neurol 2012; 8: 647-656.
4. Popescu BF, Lucchinetti CF,. Pathology of demyelinating diseases. Annu Rev Pathol 2012; 7: 185-217.
5. Kutzelnigg A, Lassmann H,. Cortical lesions and brain atrophy in MS. J Neurol Sci 2005; 233: 55-59.
6. Confavreux C, Vukusic S,. Natural history of multiple sclerosis: a unifying concept. Brain 2006; 129 (pt 3): 606-616.
7. McDonald WI, Compston A, Edan G, et al., Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 2001; 50: 121-127.
8. Poser CM, Paty DW, Scheinberg L, et al., New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-231.
9. Lublin FD, Reingold SC,. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996; 46: 907-911.
10. Hart MN, Earle KM,. Haemorrhagic and perivenous encephalitis: a clinical-pathological review of 38 cases. J Neurol Neurosurg Psychiatry 1975; 38: 585-591.
11. Roemer SF, Parisi JE, Lennon VA, et al., Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 2007; 130 (pt 5): 1194-1205.
12. Wingerchuk DM, Hogancamp WF, O'Brien PC, Weinshenker BG,. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 1999; 53: 1107-1114.
13. Frischer JM, Bramow S, Dal-Bianco A, et al., The relation between inflammation and neurodegeneration in multiple sclerosis brains. Brain 2009; 132 (pt 5): 1175-1189.
14. Bruck W, Porada P, Poser S, et al., Monocyte/macrophage differentiation in early multiple sclerosis lesions. Ann Neurol 1995; 38: 788-796.
15. Prineas JW, Kwon EE, Cho ES, et al., Immunopathology of secondary-progressive multiple sclerosis. Ann Neurol 2001; 50: 646-657.
16. Barkhof F, Bruck W, De Groot CJ, et al., Remyelinated lesions in multiple sclerosis: magnetic resonance image appearance. Arch Neurol 2003; 60: 1073-1081.
17. Patrikios P, Stadelmann C, Kutzelnigg A, et al., Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129 (pt 12): 3165-3172.
18. Agresti A,. Categorial data analysis. 2nd ed. Hoboken, NJ: Wiley-Interscience, 2002.
19. Capello E, Mancardi GL,. Marburg type and Balo's concentric sclerosis: rare and acute variants of multiple sclerosis. Neurol Sci 2004; 25 (suppl 4): S361-S363.
20. Metz I, Weigand SD, Popescu BF, et al., Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann Neurol 2014; 75: 728-738.
21. Breij EC, Brink BP, Veerhuis R, et al., Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63: 16-25.
22. Filippi M, Rocca MA, Barkhof F, et al., Association between pathological and MRI findings in multiple sclerosis. Lancet Neurol 2012; 11: 349-360.
23. Popescu BF, Pirko I, Lucchinetti CF,. Pathology of multiple sclerosis: where do we stand? Continuum (Minneap Minn) 2013; 19: 901-921.
24. Confavreux C, Vukusic S,. The clinical course of multiple sclerosis. Handb Clin Neurol 2014; 122: 343-369.
25. Cottrell DA, Kremenchutzky M, Rice GP, et al., The natural history of multiple sclerosis: a geographically based study. 5. The clinical features and natural history of primary progressive multiple sclerosis. Brain 1999; 122 (pt 4): 625-639.
26. Weiner HL,. A shift from adaptive to innate immunity: a potential mechanism of disease progression in multiple sclerosis. J Neurol 2008; 255 (suppl 1): 3-11.
27. Rovaris M, Barkhof F, Bastianello S, et al., Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. J Neurol 1999; 246: 920-925.
28. Tan IL, van Schijndel RA, Fazekas F, et al., Image registration and subtraction to detect active T(2) lesions in MS: an interobserver study. J Neurol 2002; 249: 767-773.
29. Erbayat Altay E, Fisher E, Jones SE, et al., Reliability of classifying multiple sclerosis disease activity using magnetic resonance imaging in a multiple sclerosis clinic. JAMA Neurol 2013; 70: 338-344.
30. Liguori M, Meier DS, Hildenbrand P, et al., One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. J Neurol Neurosurg Psychiatry 2011; 82: 1125-1131.
31. Vellinga MM, Oude Engberink RD, Seewann A, et al., Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 2008; 131 (pt 3): 800-807.
32. Cook SD, Dhib-Jalbut S, Dowling P, et al., Use of magnetic resonance imaging as well as clinical disease activity in the clinical classification of multiple sclerosis and assessment of its course: a report from an International CMSC Consensus Conference, March 5-7, 2010. Int J MS Care 2012; 14: 105-114.
33. Jones BC, Nair G, Shea CD, et al., Quantification of multiple-sclerosis-related brain atrophy in two heterogeneous MRI datasets using mixed-effects modeling. Neuroimage Clin 2013; 3: 171-179.
34. Kornek B, Storch MK, Weissert R, et al., Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000; 157: 267-276.
35. Bramow S, Frischer JM, Lassmann H, et al., Demyelination versus remyelination in progressive multiple sclerosis. Brain 2010; 133: 2983-2998.
36. Rist JM, Franklin RJ,. Taking ageing into account in remyelination-based therapies for multiple sclerosis. J Neurol Sci 2008; 274: 64-67.
37. Tutuncu M, Tang J, Zeid NA, et al., Onset of progressive phase is an age-dependent clinical milestone in multiple sclerosis. Mult Scler 2013; 19: 188-198.
38. Kutzelnigg A, Lucchinetti CF, Stadelmann C, et al., Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 2005; 128: 2705-2712.
39. Confavreux C, Vukusic S,. Age at disability milestones in multiple sclerosis. Brain 2006; 129 (pt 3): 595-605.
40. Voskuhl RR, Gold SM,. Sex-related factors in multiple sclerosis susceptibility and progression. Nat Rev Neurol 2012; 8: 255-263.
41. Luchetti S, van Eden CG, Schuurman K, et al., Gender differences in multiple sclerosis: induction of estrogen signaling in male and progesterone signaling in female lesions. J Neuropathol Exp Neurol 2014; 73: 123-135.